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Abstract: A novel one-pot multicomponent reaction to synthesize substituted imidazopyrazines
is described. In brief, 1H-(imidazol-5-yl)-N-substituted methanamines react with aldehydes and
isocyanides in methanol at room temperature to give imidazopyrazine derivatives in excellent yields.
The imidazole nitrogen atom was able to intercept the nascent nitrilium ion, channeling the reaction
toward to the sole formation of imidazopyrazines, suppressing the competitive formation of other
possible side products deriving from the reaction with the high-energy nitrilium ion. The number of
examples and the variability of the nature of isocyanides, aldehydes, and amine components herein
employed, witness the robustness of this novel methodology.
Keywords: multicomponent reactions; interrupted Ugi reactions; isocyanides
1. Introduction
Although multistep synthesis is the only possible choice for the preparation of highly complex
natural products, it is important to keep in mind the actual feasibility and pragmatic aspects of those
synthetic sequences. A recent paper [1] demonstrated that for the famous 49 steps Woodward’s
synthesis of chlorophyll a, 1 mg of product would have required 230 kg of ethyl acetoacetate, the first
chemical used in that project. Therefore, it is important, for concepts like “efficiency of synthesis” [2]
and “reaction mass efficiency” [3], to consider the real practical application of any synthetic project.
For this reason, the identification of novel reactions enabling the one-pot assembly of compounds
of medium structural complexity is an important field of research with significant implications for
all chemistry branches [4]. Multicomponent reactions (MCRs) are among these types of reactions,
allowing for the formation of three or four covalent bonds in one single chemical operation with a net
reduction of time and chemical waste. When providing the desired chemical output, MCRs usually
represent the most efficient choice available to chemists [5–15].
Two more advantages of these MCRs are the rapid generation of a library of compounds, and the
possibility to generate molecular scaffolds, which are difficult or in some cases impossible to obtain
by the classical two-component chemistry [16]. Finally, when compared to a multistep synthesis, the
excellence of a multicomponent reaction can be easily and rapidly ascertained by a large number of
chemists shortly after publication. Characteristics such as yield, ease of purification, and versatility
can be easily proved, and their scope expanded, beyond the original design [17,18].
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One of the most important and versatile multicomponent reactions available to chemists is the Ugi
reaction [8], a four-component one-pot reaction among equimolar amounts of amines (1), aldehydes
(2), isocyanides (3), and carboxylic acids (5) which yields α-acylaminoamides (6) under mild reaction
conditions in an alcoholic solvent (Scheme 1).
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Scheme 1. The Ugi reaction.
Thanks to its versatility, this reaction can also be used as the conceptual starting point for
the discovery of novel MCRs, for example, by replacing one of the components with a suitable
isostere [19]. Another possibility consists in removing the carboxylic acid, allowing the nitrilium ion
intermediate (4) to be intramolecularly intercepted by a passive nucleophile unable to interfere with
the initial elementary steps of the Ugi reaction. This strategy is known as interrupted Ugi reaction and,
despite its intrinsic potentiality, it has not been fully exploited by the scientific community [20–28].
The interrupted Ugi reaction could be a very powerful tool to create sets of multi-functionalized and
drug-like heterocycles, as exemplified in Figure 1.
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Figure 1. Examples of heterocycles obtained through an interrupted Ugi reaction.
Herein, we would like to disclose a novel interrupted Ugi reaction, exploiting for the first time the
imidazol ring, as a soft nucleophile able t intramolecularly intercept the nascent nitrilium ion. This
inter ediate nables the f rmation f otherwise sy hetically cha lenging substituted imidazopyrazines,
in excell nt yields and under mild reaction conditions (r.t. in M OH) Multicomponent reactions
represent a powerful chemical tool to expedite medic nal chemistry and early drug discovery
programs [29], esp cially when combined ith automation and flow synthesis [30–32].
2. Results and Discussion
To perform this task, we synthesized the corresponding imidazole N-substituted methanamines
via reductive amination between formylimidazole derivatives (7–9) and primary amines (Scheme 2),
preparing eight different building blocks (13–20) (Figure 2).
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overnight (Figure 3).
lec les , ,    I   f  
 
 
 . t i  f i i l  - tit t  t i . 
 
i  . t i  i i l  - tit t  t i . 
it  t  iff t i i l  - tit t  t i ,  t  i  t t   i  
t l  iff t i i  ( )  t l  l  ( ) i  t l, t  t t  
i t ( i  ). 
 
i  . I i   l  . 
Figure 3. Isocyanides and aldehydes used.
Molecules 2019, 24, 1959 4 of 17
To our delight, all the attempted reactions consistently resulted in the formation of the desired
imidazopyrazines (45–80), usually in excellent yields, without the formation of any by-products
(Figure 4).
In detail, yields ranged from 95% to 25% and showed to be unaffected by the nature of isocyanides.
Indeed, we were able to successfully use all kinds of isocyanides: aromatic, primary, secondary, and
tertiary aliphatic, and isocyanoacetate, without noting a significant decrease in yield. Aliphatic and
aromatic aldehydes containing either electron-withdrawing or electron-donating groups reacted in
similar ways. A reduction in yield was observed above all with heterocyclic aldehydes 35 and 37
(Figure 3). Except for compounds 77 and 78, which were obtained as a mixture of isomers, we have
generally observed the formation of one single geometrical isomer for the amidines. To further confirm
this data, an X-ray crystallographic analysis of compound 79 was also performed (Figure 5).
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The crystallographic data showed that the amidine adopts an E configuration about the C6 = N3
double bond; the piperazine ring is characterized by an almost half-chair conformation (Cremer–Pople
puckering parameters [34] are: QT = 0.428(1) Å, θ = 46.3(5)◦ and ϕ = −160(1)◦). The chloro-benzene
substituent is in axial conformation and it is perpendicularly oriented with respect to the imidazole
moiety (dihedral angle of 89(1)◦). The bicyclic core presents a certain degree of electron delocalization, as
shown by the shortening of the N2-C6 1.434(2) Å and C3-C4 1.498(2) Å bond lengths. The conformation
of N4-side chain is mainly characterized by the torsional angles ω1 C4-N4-C17-C18 of 60.8(1)◦, ω2
N4-C17-C18-C19 of 53.4(1)◦, andω3 C18-C19-C20-C21 of 63.6(1)◦.
In the light of these results, in Scheme 3 we propose the following reaction mechanism: the
secondary amine A reacts with the carbonyl compound B in methanol, forming the iminium ion C
after the loss of a molecule of water [35]. The iminium ion cannot undergo intramolecular cyclization
through the nitrogen atom of imidazole, being disfavored by an incorrect orbital overlapping [36],
thus allowing for the isocyanide D to react, forming the highly energetic nitrilium ion E. A fast and
irreversible 6-exo-dig intramolecular trapping by means of the nitrogen atom of imidazole affords
compound F. As suggested by one of the reviewers as many 5-endo-trig processes, although unfavoured,
are observed, it could be possible that the putative aminal formed via a 5-endo-trig cyclization may
undergo reopening and can be irreversibly trapped by the isocyanide. Note that the nitrogen atom
attacks the nitrilium ion in a stereoselective way [37,38], affording the amidines in Z configuration.
Finally, due to a peri interaction, compound F adopts a stable E configuration G by nitrogen inversion.
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3. Materials and Methods
3.1. Solvents and Reagents
Commercially available solvents and reagents were used without further purification.
Tetrahydrofuran (THF) was distilled immediately before use from Na/benzophenone under a slight
positive atmosphere of dry nitrogen. When needed, the reactions were performed in oven-dried
glassware under a positive pressure of dry nitrogen.
3.2. Chromatography
Column chromatography was performed on silica gel (Merck Kieselgel 60, 230–400 mesh ASTM)
using the indicated eluents. Thin layer chromatography (TLC) was carried out on 5 × 20 cm plates with
a layer thickness of 0.25 mm (Merck Silica gel 60 F254, Merck KGaA, Darmstadt, Germany). When
necessary they were visualized using KMnO4 reagent or Dragendorff reagent.
3.3. Spectra
Infrared spectra were recorded on an FT-IR Thermo-Nicolet Avatar spectrometer with absorption
maxima (νmax) recorded in wavenumbers (cm−1). NMR spectra were recorded using a JEOL ECP
300 MHz spectrometer. Chemical shifts (δ) are quoted in parts per million referenced to the residual
solvent peak. The multiplicity of each signal is designated using the following abbreviations: s, singlet;
d, doublet; t, triplet; q, quartet; quint, quintet; sext, sextet; hept, heptet; m, multiplet; br s, broad
singlet. Coupling constants (J) are reported in Hertz (Hz) (for more data see Supplementary Materials).
Mass spectra were recorded on a Thermo Finningan LCQ-deca XP-plus mass spectrometer (Waltham,
Massachusetts, USA) equipped with an ESI source and an ion trap detector. Melting points were
determined using a Stuart Scientific SMP3 apparatus and remain uncorrected.
3.4. Preparation of econdary Amines (13–20)
The appropriate imidazolecarboxaldehyde derivative (10 mmol, 1 equiv.) was dissolved in
methanol. The amine (1 equiv.) in dry THF (5.0 mL), and activated 4 Å molecular sieves (2.00 g) were
added. The reaction mixture was stirred at room temperature, under nitrogen for 12 h. Then, sodium
borohydride (1.2 equiv.) was added portionwise and the reaction was stirred at room temperature.
After 3 h water was added, and the mixture was stirred for 10 min. Molecular sieves were filtered off
through a Celite pad. The filtrate was evaporated under reduced pressure. The residue was taken
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up with EtOAc and the organic layer was washed with 2N NaOH (× 1), dried over sodium sulfate
and concentrated in vacuo. The crude material was purified by column chromatography using the
indicated eluents.
N-((1H-imidazol-5-yl)methyl)-1-phenylmethanamine (13). The crude material was purified by
column chromatography (EtOAc/MeOH 90:10 + 1% NH4OH) to give the product as a white solid
(1.01 g, yield 54%). 1H-NMR (300 MHz, CD3OD) δ 7.61 (s, 1H), 7.30–7.22 (m, 5H), 6.97 (s, 1H), 3.72 (br
s, 4H); 13C-NMR (75 MHz, CD3OD) δ 139.3, 135.8, 135.2, 128.4, 128.3, 127.0, 117.1, 52.4, 44.4; IR (KBr)
3551, 3411, 3235, 2842, 1564, 1492, 1454, 1322, 1085, 1066 νmax/cm−1; m.p. 103–104 ◦C; MS (ESI) m/z
Calcd for C11H14N3+: 188.1183; found: 188.1184 [M + H]+.
N-((1H-imidazol-5-yl)methyl)-1-(4-chlorophenyl)methanamine (14). The crude material was
purified by column chromatography (EtOAc/MeOH 90:10 + 1% NH4OH) to give the product as
yellow oil (1.33 g, yield 60%). 1H-NMR (300 MHz, CD3OD) δ 7.63 (s, 1H), 7.33–7.28 (m, 4H), 6.99 (s,
1H), 3.71 (s, 2H), 3.70 (s, 2H); 13C-NMR (75 MHz, CD3OD) δ 139.5, 137.1, 136.6, 134.1, 131.3, 129.7, 118.5,
53.0, 46.0; IR (neat) 3089, 2841, 1490, 1452, 1089, 1014, 936, 802, 623 νmax/cm−1; MS (ESI) m/z Calcd for
C11H13ClN3+: 222.0793; found: 222.0795 [M + H]+.
N-((1H-imidazol-5-yl)methyl)hexan-1-amine (15). The crude material was purified by column
chromatography (dichloromethane/ methanol 90:10) to give the product as a yellowish oil (1.77 g, 98%
yield). 1H NMR (400 MHz, CD3OD) δ 7.61 (s, 1H), 6.97 (s, 1H), 3.70 (s, 2H), 2.58–2.55 (m, 2H), 1.52–1.47
(m, 2H), 1.33–1.30 (m, 6H), 0.91–0.88 (m, 3H); 13C NMR (100 MHz, CD3OD) δ 135.1, 134.8, 117.0, 48.2,
44.6, 31.4, 28.5, 26.6, 22.2, 13.0. IR (neat) 3088, 2925, 2855, 1466, 1089, 822, 626 νmax/cm−1; MS (ESI) m/z
Calcd for C10H20N3+: 182.1652; found: 182.1655 [M + H]+.
N-((1H-imidazol-5-yl)methyl)-1-(4-methoxyphenyl)methanamine (16). The crude material was
purified by column chromatography (dichloromethane/ methanol 90:10) to give the product as
a yellowish oil (0.977 g, 45% yield). 1H NMR (400 MHz, CD3OD) δ 7.62 (s, 1H), 7.23 (d, J = 8.4 Hz, 2H),
6.98 (s, 1H), 6.86 (d, J = 8.4 Hz, 2H), 3.76 (s, 3H), 3.70 (s, 2H), 3.67 (s, 2H); 13C NMR (100 MHz, CD3OD)
δ 158.7, 135.7, 135.3, 131.5, 129.5, 117.5, 113.8, 55.2, 52.4, 45.0. IR (neat) 3117, 2836, 1611, 1512, 1456,
1244, 1089, 1032, 815, 626 νmax/cm−1; MS (ESI) m/z Calcd for C12H16N3O+: 218.1288; found: 218.1291
[M + H]+.
N-((1H-imidazol-5-yl)methyl)aniline (17). The crude material was purified by column
chromatography (dichloromethane/ methanol 98:2) to give the product as a yellowish oil (1.59 g, 92%
yield). 1H NMR (400 MHz, CD3OD) δ 7.58 (s, 1H), 7.10–7.06 (m, 2H), 6.93 (s, 1H), 6.67–6.59 (m, 3H),
4.23 (s, 2H); 13C NMR (100 MHz, CD3OD) δ 148.5, 128.5, 117.0, 112.9, 40.4. IR (neat) 3388, 3049, 2815,
2632, 1605, 1505, 1317, 1002, 836, 750 νmax/cm−1; Mp 127–128 ◦C; MS (ESI) m/z Calcd for C10H12N3+:
174.1026; found: 174.1028 [M + H]+.
N-((1H-imidazol-2-yl)methyl)-1-phenylmethanamine (18). The crude material was purified by
column chromatography (EtOAc/MeOH 95:5 + 1% NH4OH and EtOAc/MeOH 90:10 + 1% NH4OH) to
give the product as yellow oil (0.972 g, yield 52%). 1H-NMR (300 MHz, CD3OD) δ 7.26–7.18 (m, 5H),
6.97 (s, 2H), 3.78 (s, 2H), 3.66 (s, 2H); 13C-NMR (75 MHz, CD3OD) δ 147.9, 140.4, 129.4 (2C), 128.2, 122.7,
53.8, 46.3; IR (neat) 2919, 1452, 1098, 986, 855, 736, 697 νmax/cm−1; MS (ESI) m/z Calcd for C11H14N3+:
188.1183; Found: 188.1184 [M + H]+.
N-((1H-benzo[d]imidazol-2-yl)methyl)-1-phenylmethanamine (19). The crude material was purified
by column chromatography (Pet/EtOAc 10:90) to give the product as yellow solid (0.640 g, yield 27%).
1H-NMR (300 MHz, CD3OD) δ 7.54–7.51 (m, 2H), 7.36–7.19 (m, 7H), 4.01 (s, 2H), 3.81(s, 2H); 13C-NMR
(75 MHz, CD3OD) δ 155.0, 140.6, 129.4, 128.2, 123.4, 115.6, 54.1, 47.0; IR (neat) 3555, 3414, 3028, 2838,
1618, 1437, 1269, 1024, 750 νmax/cm−1; m.p. 143–145 ◦C; MS (ESI) m/z Calcd for C15H16N3+: 238.1339;
found: 238.1339 [M + H]+.
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N-((1H-benzo[d]imidazol-2-yl)methyl)-2-phenylethanamine (20). The crude material was purified
by column chromatography (Pet/EtOAc 20:80 and EtOAc/MeOH 90:10) to give the product as yellow
solid (1.00 g, yield 40%). 1H-NMR (300 MHz, CD3OD) δ 7.53–7.49 (m, 2H), 7.26–7.12 (m, 7H), 4.01 (s,
2H), 2.92–2.87 (m, A2B2 system, 2H), 2.83–2.78 (m, A2B2 system, 2H); 13C-NMR (75 MHz, CD3OD) δ
154.9, 141.0, 129.6, 129.5, 127.2, 123.5, 115.7, 51.7, 47.5, 36.9; IR (neat) 3554, 3415, 2950, 2817, 1618, 1537,
1453, 1424, 1275, 1125, 1025, 751, 704 νmax/cm−1; m.p. 141–143 ◦C; MS (ESI) m/z Calcd for C16H18N3+:
252.1496; Found: 252.1497 [M + H]+.
3.5. Synthesis of Substituted Imidazopyrazines and Benzoimidazopyrazines (45–80)
The secondary amine (0.5 mmol, 1 equiv.) was dissolved in methanol (2.0 mL). Aldehyde
(0.5 mmol, 1 equiv.) and isocyanide (0.5 mmol, 1 equiv.) were added and the reaction was stirred at
room temperature under nitrogen for 18 h. The reaction mixture was concentrated under reduced
pressure and the crude material was purified by column chromatography.
(E)-N-(7-benzyl-6-hexyl-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)pentan-1-amine (45).
The crude material was purified by column chromatography (Pet/EtOAc 90:10 and Pet/EtOAc 70:30) to
give the product as orange oil (153 mg, yield 75%). 1H-NMR (300 MHz, CDCl3) δ 8.32 (s, 1H), 7.29–7.27
(m, 5H), 6.78 (s, 1H), 4.13 (d, J = 17.1 Hz, AB system, 1H), 3.80–3.68 (m, 3H), 3.53 (d, J = 13.2 Hz, AB
system, 1H), 3.24–3.22 (m, 2H), 1.78–1.16 (m, 16H), 1.06–0.88 (m, 6H); 13C-NMR (75 MHz, CDCl3) δ
150.0, 137.9, 132.8, 128.9, 128.5, 127.7, 124.9, 124.6, 58.9, 54.8, 48.3, 40.7, 31.8, 30.9, 29.7, 28.8, 25.9, 22.7,
22.6, 14.1. IR (neat) 2953, 2927, 2857, 1671, 1461, 1347, 1093, 923, 818, 699 νmax/cm−1; MS (ESI) m/z Calcd
for C24H37N4+: 381.3013; Found: 381.3006 [M + H]+.
(E)-N-(7-benzyl-6-hexyl-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)-2-phenylethanamine
(46). The crude material was purified by column chromatography (Pet/EtOAc 90:10) to give the
product as orange oil (160 mg, yield 72%). 1H-NMR (300 MHz, CDCl3) δ 8.38, (s, 1H), 7.31–7.17 (m,
10H), 6.79 (s, 1H), 4.07 (d, J = 16.8 HZ, AB system, 1H), 3.75–3.47 (m, 5H), 3.25 (d, J = 13.2 Hz, AB
system, 1H), 3.04–2.84 (m, 2H), 1.68–1.48 (m, 2H), 1.28–1.14 (m, 8H), 0.89–0.83 (m, 3H); 13C-NMR (75
MHz, CDCl3) δ 150.7, 140.0, 138.0, 135.4, 129.2, 128.8, 128.6, 128.5, 127.6, 126.4, 125.1, 124.6, 58.7, 55.1,
50.3, 40.4, 37.8, 31.8, 28.8 (2C), 25.9, 22.7, 14.2. IR (neat) 2925, 2856, 1671, 1460, 1347, 1089, 923, 744, 698
νmax/cm−1; MS (ESI) m/z Calcd for C27H35N4+: 415.2857; found: 415.2853 [M + H]+.
(E)-N-(7-benzyl-6-hexyl-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)-1-phenylmethanamine
(47). The crude material was purified by column chromatography (Pet/EtOAc 70:30) to give the
product as orange oil (118 mg, yield 55%). 1H-NMR (300 MHz, CDCl3) δ 8.41, (s, 1H), 7.33–7.23
(m, 10H), 6.81 (s, 1H), 4.52 (s, 2H), 4.17 (d, J = 16.8 Hz, AB system, 1H), 3.91–3.71 (m, 3H), 3.54 (d,
J = 12.8 Hz, AB system, 1H), 1.82–1.20 (m, 10H), 0.97–0.89 (m, 3H); 13C-NMR (75 MHz, CDCl3) δ 151.4,
139.5, 137.8, 133.0, 129.0, 128.6, 127.8. 127.5, 127.1, 125.2, 124.6, 59.0, 55.1, 51.8, 40.7, 31.8, 28.8 (2C), 26.0,
22.7, 14.2; IR (neat) 2926, 1671, 1460, 1346, 1213, 1086, 922, 734, 697 νmax/cm−1; MS (ESI) m/z Calcd for
C26H33N4+: 401.2700; found: 401.2699 [M + H]+.
(E)-N-(7-benzyl-6-hexyl-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)-2-methylpropan-2-amine
(48). The crude material was purified by column chromatography (Pet/EtOAc 95:5 and Pet/EtOAc
70:30) to give the product as brown amorphous solid (154 mg, yield 79%). 1H-NMR (300 MHz, CDCl3)
δ 8.26 (s, 1H), 7.29–7.26 (m, 5H), 6.71 (s, 1H), 4.08 (d, J = 17.1 Hz, AB system, 1H), 3.93–3.89 (m, 1H),
3.70–3.65 (m, 3H), 1.84–1.21 (m, 19H), 1.10–0.90 (m, 3H); 13C-NMR (75 MHz, CDCl3) δ 146.2, 138.1,
133.1, 128.4 (2C), 127.4, 124.9, 124.5, 58.5 (2C), 54.5, 39.6, 31.7, 31.5, 29.7, 28.8, 26.0, 22.6, 14.0; IR (KBr)
2958, 2924, 2858, 1670, 1455, 1344, 1198, 1095, 738, 652 νmax/cm−1; MS (ESI) m/z Calcd for C23H35N4+:
367.2857; found: fragment ion (loss of 2-methyl-N-methylenepropan-2-amine moiety): 284.2121 [M + H]+.
(E)-N-(7-benzyl-6-isopropyl-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)cyclohexanamine
(49). The crude material was purified by column chromatography (Pet/EtOAc 70:30) to give the
product as yellow solid (121 mg, yield 69%). 1H-NMR (300 MHz, CDCl3) δ 8.26 (s, 1H), 7.30–7.25 (m,
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5H), 6.72 (s, 1H), 4.11 (d, J = 17.4 Hz, AB system, 1H), 3.71–3.66 (m, 3H), 3.49 (d, J = 10.7 Hz, AB system,
1H), 3.29–3.30 (m, 1H), 1.95–1.92 (m, 1H), 1.79–1.45 (m, 6H), 1.24–1.20 (m, 7H), 0.93 (d, J = 6.7 Hz, 3H);
13C-NMR (75 MHz, CDCl3) δ 146.6, 138.2, 132.9, 128.5 (2C), 127.5, 125.3, 124.5, 62.5, 59.0, 57.4, 40.2, 34.7,
33.8, 27.9, 25.6, 24.4, 24.3, 20.2, 20.0; IR (KBr) 3033, 2922, 2850, 1672, 1618, 1455, 1340, 1245, 1214, 1090,
815 νmax/cm−1; m.p. 154–155 ◦C; MS (ESI) m/z Calcd for C22H31N4+: 351.2544; found: fragment ion
(loss of N-methylenecyclohexanamine moiety): found: 242.1653 [M + H]+.
(E)-N-(7-benzyl-6-isopropyl-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)cyclopropanamine
(50). The crude material was purified by column chromatography (Pet/EtOAc 70:30) to give the
product as yellow solid (108 mg, yield 70%). 1H-NMR (300 MHz, CDCl3) δ 8.20 (s, 1H), 7.30–7.25 (m,
5H), 6.78 (s, 1H), 4.21 (d, J = 17.1 Hz, AB system, 1H), 3.81–3.47 (m, 4H), 2.70–2.63 (m, 1H), 2.56–2.42
(m, 1H), 2.06–1.95 (m, 1H), 1.24–0.81 (m, 9H); 13C-NMR (75 MHz, CDCl3) δ 148.6, 138.0, 132.5, 129.1,
128.4, 127.6, 124.8, 124.6, 61.0, 59.1, 41.4, 31.7, 28.3, 20.1 (2C), 9.6, 8.9; IR (KBr) 3002, 2960, 2925, 2870,
1668, 1454, 1359, 1344, 1246, 1090 νmax/cm−1; m.p. 107–108 ◦C; MS (ESI) m/z Calcd for C19H25N4+:
309.2074; found: 309.2072 [M + H]+.
(E)-N-(7-benzyl-6-isopropyl-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)-2-phenylethanamine
(51). The crude material was purified by column chromatography (Pet/EtOAc 90:10 and Pet/EtOAc
70:30) to give the product as brown oil (113.5 mg, yield 61%). 1H-NMR (300 MHz, CDCl3) δ 8.34 (s,
1H), 7.29–7.16 (m, 10H), 6.76 (s, 1H), 4.12 (d, J = 17.1 Hz, AB system, 1H), 3.69 (d, J = 17.1 Hz, AB
system, 1H), 3.54–3.47 (m, 3H), 3.34–3.20 (m, 2H), 3.05–2.84 (m, 2H), 2.05–1.90 (m, 1H), 1.14–1.11 (m,
3H), 0.86–0.83 (m, 3H); 13C-NMR (75 MHz, CDCl3) δ 149.6, 140.0, 138.1, 132.8, 129.2, 128.6 (2C), 128.5,
127.6, 126.4, 125.2, 124.8, 61.3, 58.6, 51.5, 40.8, 37.8, 28.4, 20.1, 19.9; IR (neat) 2960, 1672, 1494, 1456, 1353,
1218, 1103, 743, 698 νmax/cm−1; MS (ESI) m/z Calcd for C24H29N4+: 373.2387; found: fragment ion (loss
of N-methylene-2-phenylethanamine moiety): found: 242.1654 [M + H]+.
(E)-methyl2-((7-benzyl-6-isopropyl-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)amino)-acetate
(52). The crude material was purified by column chromatography (Pet/EtOAc 70:30) to give the
product as brown oil (92 mg, yield 54%). 1H-NMR (300 MHz, CDCl3) δ 8.33 (s, 1H), 7.28–7.25 (m, 5H),
6.77 (s, 1H), 4.21 (d, J = 17.4 Hz, AB system, 1H), 4.05 (br s, 2H), 3.81–3.76 (m, 5H), 3.60 (d, J = 13.2 Hz,
AB system, 1H), 3.27 (d, J = 10.7 Hz, 1H), 2.02–1.93 (m, 1H) 1.13 (d, J = 6.4 Hz, 3H), 0.86 (d, J = 7.8 Hz,
3H); 13C-NMR (75 MHz, CDCl3) δ 170.2, 152.9, 137.7, 133.2, 128.8, 128.6, 127.8, 125.0 (2C), 61.0, 59.0,
52.3, 51.2, 41.2, 28.3, 20.0, 19.8; IR (neat) 2961, 1743, 1678, 1465, 1358, 1198, 1178, 741 νmax/cm−1; MS
(ESI) m/z Calcd for C19H25N4O2+: 341.1973; found: 341.1971 [M + H]+.
(E)-N-(7-benzyl-6-hexyl-7,8-dihydroimidazo[1,2-a]pyrazin-5(6H)-ylidene)pentan-1-amine (53).
The crude material was purified by column chromatography (Pet/EtOAc 80:20) to give the product as
yellow oil (129 mg, yield 68%). 1H-NMR (300 MHz, CDCl3) δ 7.62 (s, 1H), 7.31–7.29 (m, 5H), 7.00 (s,
1H), 4.25 (d, J = 17.8 Hz, AB system, 1H), 3.93 (d, J = 17.8 Hz, AB system, 1H), 3.89–3.76 (m, 3H), 3.58
(d, J = 13.2 Hz, AB system, 1H), 3.23 (t, J = 6.7 Hz, 2H) 1.75–1.27 (m, 15H), 0.94–0.87 (m, 6H); 13C-NMR
(75 MHz, CDCl3) δ 150.9, 143.6, 137.7, 129.0, 128.6, 128.4, 127.8, 113.5, 59.4, 54.4, 48.7, 44.5, 31.8, 31.0,
29.7, 28.8 (2C), 26.0, 22.7, 22.6, 14.2 (2C); IR (neat) 2927, 2857, 1670, 1491, 1455, 1413, 1289, 1093, 889, 743,
698 νmax/cm−1; MS (ESI) m/z Calcd for C24H37N4+: 381.3013; found: 381.3006 [M + H]+.
(E)-N-(7-benzyl-6-isopropyl-7,8-dihydroimidazo[1,2-a]pyrazin-5(6H)-ylidene)-1-phenylmethanamine
(54). The crude material was purified by column chromatography (Pet/EtOAc 80:20) to give the
product as yellow oil (147 mg, yield 77%). 1H-NMR (300 MHz, CDCl3) δ 7.69 (s, 1H), 7.36–7.23 (m,
10H), 7.03 (s, 1H), 4.54–4.33 (m, 3H), 3.96–3.80 (m, 2H), 3.61–3.51 (m, 2H), 2.06–1.96 (m, 1H), 1.19 (d,
J = 6.4 Hz, 3H), 0.93 (d, J = 6.4 Hz, 3H); 13C-NMR (75 MHz, CDCl3) δ 150.8, 143.9, 139.6, 137.7, 128.9,
128.6, 128.5 (2C), 127.8, 127.5, 127.0, 114.0, 60.7, 59.6, 53.1, 45.0, 28.6, 20.2, 20.0; IR (neat) 2961, 1671,
1491, 1410, 1289, 1258, 1100, 737, 697 νmax/cm−1; MS (ESI) m/z Calcd for C23H27N4+: 359.2231; found:
359.2229 [M + H]+.
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(E)-N-(7-benzyl-6-isopropyl-7,8-dihydroimidazo[1,2-a]pyrazin-5(6H)-ylidene)cyclopropanamine
(55). The crude material was purified by column chromatography (Pet/EtOAc 70:30) to give the
product as yellow oil (91 mg, yield 56%). 1H-NMR (300 MHz, CDCl3) δ 7.45 (br d, 1H), 7.29–7.24 (m,
5H), 6.96 (br d, 1H), 4.30 (d, J = 18.0 Hz, AB system, 1H), 3.92–3.78 (m, 2H), 3.61–3.47 (m, 2H), 2.65–2.61
(m, 1H), 2.02–1.86 (m, 1H), 1.19–0.78 (m, 10H); 13C-NMR (75 MHz, CDCl3) δ 149.2, 143.3, 137.7, 129.4,
129.1, 128.4, 128.2, 127.6, 113.6, 60.5, 59.6, 45.1, 31.9, 28.3, 20.1, 20.0, 9.6, 8.9; IR (neat) 2962, 1665, 1530,
1488, 1415, 1367, 1289, 1261, 1087, 743, 698 νmax/cm−1; MS (ESI) m/z Calcd for C19H25N4+: 309.2074;
found: 309.2072 [M + H]+.
(E)-N-(7-benzyl-6-phenyl-7,8-dihydroimidazo[1,2-a]pyrazin-5(6H)-ylidene)cyclohexanamine (56).
The crude material was purified by column chromatography (Pet/EtOAc 90:10 and Pet/EtOAc 70:30)
to give the product as yellow oil (114 mg, yield 56%). 1H-NMR (300 MHz, CDCl3) δ 7.78 (br d, 1H),
7.41–7.23 (m, 10H), 7.02 (br d, 1H), 5.04 (s, 1H), 3.91–3.67 (m, 4H), 3.09–2.99 (m, 1H), 1.73–1.00 (m, 10H);
13C-NMR (75 MHz, CDCl3) δ 146.3, 144.3, 137.5, 134.7, 129.0, 128.9, 128.7, 128.6, 128.5, 128.1, 127.9,
113.7, 58.9, 58.7, 57.2, 44.9, 34.3, 33.6, 25.5, 24.2, 24.1; IR (neat) 2928, 2853, 1668, 1536, 1492, 1450, 1412,
1289, 1090, 740, 698 νmax/cm−1; MS (ESI) m/z Calcd for C25H29N4+: 385.2387; found: 385.2387 [M + H]+.
(E)-N-(7-benzyl-6-isopropyl-7,8-dihydroimidazo[1,2-a]pyrazin-5(6H)-ylidene)-[1,1′-biphenyl]-4-amine
(57). The crude material was purified by column chromatography (Pet/EtOAc 90:10 and Pet/EtOAc
70:30) to give the product as yellow oil (158 mg, yield 70%). 1H-NMR (300 MHz, CDCl3) δ 7.77 (br d,
1H), 7.77–7.29 (m, 12H), 7.11 (br d, 1H), 6.86 (br d, 2H), 4.32–4.14 (m, 1H), 4.02–3.84 (m, 3H), 3.70–3.63
(m, 1H), 2.07–1.97 (m, 1H), 1.11 (br d, 3H), 0.82 (br s 3H); 13C-NMR (75 MHz, CDCl3) δ 150.9, 146.0,
144.7, 140.6, 137.8, 137.0, 129.3, 128.9, 128.7, 128.6, 127.8, 127.7, 127.2, 126.8, 120.8, 114.1, 62.8, 59.7, 44.1,
28.9, 20.4 (2C); IR (neat) 2963, 1667, 1535, 1484, 1407, 1259, 1220, 908, 848, 730, 697 νmax/cm−1; MS (ESI)
m/z Calcd for C28H29N4+: 421.2387; found: 421.2386 [M + H]+.
(E)-N-(7-benzyl-6-(pyridin-3-yl)-7,8-dihydroimidazo[1,2-a]pyrazin-5(6H)-ylidene)-2-methylpropan-
2-amine (58). The crude material was purified by column chromatography (Pet/EtOAc 50:50 and
EtOAc) to give the product as yellow oil (86 mg, yield 45%). 1H-NMR (300 MHz, CDCl3) δ 8.56 (br d,
2H), 7.76 (s, 1H), 7.46–7.22 (m, 7H), 7.00 (s, 1H), 5.19 (s, 1H), 3.91–3.81 (m, 3H), 3.64 (d, J = 18.3 Hz, AB
system, 1H), 1.12 (s, 9H); 13C-NMR (75 MHz, CDCl3) δ 157.8, 150.3, 149.8, 143.8, 142.5, 137.2, 135.7,
131.4, 128.8, 128.7, 128.0, 123.5, 114.1, 59.5, 58.5, 55.0, 44.7, 31.3; IR (neat) 2970, 1674, 1454, 1418, 1360,
1294, 1206, 1092, 911, 729, 700 νmax/cm−1; MS (ESI) m/z Calcd for C22H26N5+: 360.2183; found: 360.2181
[M + H]+.
(E)-N-(7-benzyl-6-(furan-2-yl)-7,8-dihydroimidazo[1,2-a]pyrazin-5(6H)-ylidene)-2-methylpropan-
2-amine (59). The crude material was purified by column chromatography (Pet/EtOAc 90:10 and
Pet/EtOAc 70:30) to give the product as yellow oil (93 mg, yield 50%). 1H-NMR (300 MHz, CDCl3)
δ 7.63 (br d, 1H), 7.45–7.26 (m, 6H), 6.98 (br d, 1H), 6.31 (br d, 1H), 5.94–5.93 (m, 1H), 5.19 (m, 1H),
3.99–3.57 (m, 4H), 1.06 (s, 9H); 13C-NMR (75 MHz, CDCl3) δ 148.0, 144.7, 143.1, 142.7, 137.2, 129.3,
128.7, 128.2, 127.9, 114.2, 110.6, 110.5, 58.4, 54.9, 54.5, 46.7, 30.9; IR (neat) 2970, 1684, 1542, 1493, 1418,
1364, 1208, 1087, 1014, 742, 699 νmax/cm−1; MS (ESI) m/z Calcd for C21H25N4O+: 349.2023; found:
349.2022 [M + H]+.
(E)-N-(7-(4-chlorobenzyl)-6-phenyl-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)cyclohexanamine
(60). The crude material was purified by column chromatography (Pet/EtOAc 70:30) to give the
product as orange oil (167 mg, yield 80%). 1H-NMR (300 MHz, CDCl3) δ 8.48 (s, 1H), 7.41–7.26 (m, 9H),
6.74 (s, 1H), 4.99 (s, 1H), 3.81–3.63 (m, 4H), 3.12–3.08 (m, 1H), 1.74–0.88 (m, 10H); 13C-NMR (75 MHz,
CDCl3) δ 145.3, 136.3, 134.7, 133.6, 133.0, 130.2, 128.9 (2C), 128.6, 128.2, 125.1, 125.0, 59.8, 57.6, 56.9,
41.1, 34.3, 33.5, 25.5, 24.2, 24.1; IR (neat) 2928, 2854, 1669, 1488, 1462, 1347, 1191, 1088, 803, 733, 699,
653 νmax/cm−1; MS (ESI) m/z Calcd for C25H28ClN4+: 419.1997; found: 419.1998 [M + H]+.
(E)-1-((3r,5r,7r)-adamantan-1-yl)-N-(7-(4-chlorobenzyl)-6-phenyl-7,8-dihydroimidazo[1,5-a]pyrazin-
5(6H)-ylidene)methanamine (61). The crude material was purified by column chromatography
Molecules 2019, 24, 1959 12 of 17
(Pet/EtOAc 90:10 and Pet/EtOAc 70:30) to give the product as yellow oil (193 mg, yield 82%). 1H-NMR
(300 MHz, CDCl3) δ 8.49 (s, 1H), 7.36–7.26 (m, 9H), 6.71 (s, 1H), 5.18 (s, 1H), 3.81 (s, 2H), 3.59 (s,
2H), 1.96 (s, 3H), 1.70–1.50 (m, 12H); 13C-NMR (75 MHz, CDCl3) δ 142.4, 136.5, 135.9, 133.6, 133.3,
130.2, 128.9, 128.8, 128.6, 128.4, 125.6, 124.9, 63.0, 57.5, 56.1, 44.0, 41.0, 36.3, 29.7; IR (neat) 2906, 2850,
1675, 1491, 1459, 1340, 1190, 1088, 909, 804, 729, 698 νmax/cm−1; MS (ESI) m/z Calcd for C29H32ClN4+:
471.2310; found: 471.2320 [M + H]+.
(E)-methyl2-((7-(4-chlorobenzyl)-6-hexyl-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)amino)
acetate (62). The crude material was purified by column chromatography (Pet/EtOAc 80:20 and
Pet/EtOAc 60:40) to give the product as yellow oil (156 mg, yield 75%). 1H-NMR (300 MHz, CDCl3) δ
8.35 (s, 1H), 7.297.18 (m, 4H), 6.78 (s, 1H), 4.16–4.12 (m, 3H), 3.78–3.52 (m, 7H), 1.76–1.16 (m, 10H),
0.87–0.85 (m, 3H); 13C-NMR (75 MHz, CDCl3) δ 170.0, 154.0, 136.3, 133.6, 133.4, 130.2, 128.8, 125.4,
124.3, 58.2, 55.5, 52.3, 50.2, 40.5, 31.7, 29.0, 28.8, 26.0, 22.6, 14.1; IR (neat) 2927, 2856, 1746, 1673, 1464,
1351, 1197, 1176, 1087, 1014, 807, 652 νmax/cm−1; MS (ESI) m/z Calcd for C22H30ClN4O2+: 417.2052;
found: 417.2051[M + H]+.
(E)-N-(7-(4-chlorobenzyl)-6-(furan-2-yl)-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)-2-
methylpropan-2-amine (63). The crude material was purified by column chromatography
(Pet/EtOAc 90:10 and Pet/EtOAc 70:30) to give the product as yellow oil (88 mg, yield 46%). 1H-NMR
(300 MHz, CDCl3) δ 8.33 (s, 1H), 7.43–7.34 (m, 5H), 6.77 (br d, 1H), 6.33–6.32 (m, 1H), 6.01 (br d, 1H),
5.13 (s, 1H), 3.83–3.54 (m, 4H) 1.10 (s, 9H); 13C-NMR (75 MHz, CDCl3) δ 147.8, 141.7, 135.8, 133.7, 133.1,
130.4, 128.8, 126.0, 124.0, 110.7, 110.5, 57.6, 55.6, 54.6, 43.0, 30.8; IR (neat) 2969, 1685, 1490, 1461, 1346,
1201, 1089, 1014, 809, 740, 654 νmax/cm−1; MS (ESI) m/z Calcd for C21H24ClN4O+: 383.1634; found:
383.1633 [M + H]+.
(E)-N-(2-benzyl-3-hexyl-2,3-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-4(1H)-ylidene)-2-
methylpropan-2-amine (64). The crude material was purified by column chromatography
Pet/EtOAc 95:5 and Pet/EtOAc 80:20) to give the product as yellow oil (208 mg, yield 78%). 1H-NMR
(300 MHz, CDCl3) δ 8.50–8.47 (m, 1H), 7.72–7.69 (m, 1H), 7.33–7.26 (m, 7H), 4.40 (d, J = 18.3 Hz, AB
system, 1H), 4.09–4.00 (m, 2H), 3.85 (br s, 2H), 1.91–1.71 (m, 4H), 1.58–1.35 (m, 15H), 0.92–0.94 (m, 3H);
13C-NMR (75 MHz, CDCl3) δ 149.9, 149.3, 143.2, 137.9, 132.6, 128.6 (2C), 127.7, 123.5 (2C), 118.9, 116.6,
59.3, 59.2, 55.0, 44.1, 31.8, 30.2, 28.9 (2C), 26.2, 22.7, 14.1; IR (neat) 2961, 2927, 1670, 1539, 1448, 1361,
1343, 1164, 746 νmax/cm−1; MS (ESI) m/z Calcd for C27H37N4+: 417.3013; found: 417.3010 [M + H]+.
(E)-N-(2-benzyl-3-(4-chlorophenyl)-2,3-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-4(1H)-ylidene)
pentan-1-amine (65). The crude material was purified by column chromatography (Pet/EtOAc 95:5
and Pet/EtOAc 90:10) to give the product as yellow oil (119 mg, yield 52%). 1H-NMR (300 MHz,
CDCl3) δ 8.64–8.62 (m, 1H), 7.75–7.73 (m, 1H), 7.40–7.20 (m, 11H), 5.10 (s, 1H), 4.02–3.95 (m, 3H),
3.77 (d, J = 12.8 Hz, AB system, 1H), 3.32–3.11 (m, 2H), 1.71–1.67 (m, 2H), 1.41–1.30 (m, 4H), 0.92 (t,
J = 6.9 Hz, 3H); 13C-NMR (75 MHz, CDCl3) δ 150.0, 149.5, 143.1, 137.2, 134.6, 132.9, 132.2, 129.6, 129.2,
129.1, 128.9, 128.1, 124.1 (2C), 119.3, 116.7, 58.9, 58.8, 49.0, 45.5, 30.9, 29.7, 22.5, 14.1; IR (neat) 2928,
2855, 1665, 1650, 1489, 1449, 1357, 1167, 1090, 746, 698 νmax/cm−1; MS (ESI) m/z Calcd for C28H30ClN4+:
457.2154; found: 457.2157 [M + H]+.
(E)-N-(2-benzyl-3-hexyl-2,3-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-4(1H)-ylidene)
cyclohexanamine (66). The crude material was purified by column chromatography (Pet/EtOAc 95:5
and Pet/EtOAc 90:10) to give the product as yellow oil (130 mg, yield 59%). 1H-NMR (300 MHz,
CDCl3) δ 8.55–8.52 (m, 1H), 7.73–7.70 (m, 1H), 7.35–7.26 (m, 7H), 4.43 (d, J = 18.1 Hz, AB system, 1H),
4.11 (d, J = 18.1 Hz, AB system, 1H), 3.98 (dd, J1 = 10.7 Hz, J2 = 4.3 Hz, 1H), 3.83 (d, J = 13.1 Hz,
AB system, 1H), 3.70 (d, J = 13.1 Hz, AB system, 1H), 3.38–3.30 (m, 1H), 1.93–1.29 (m, 20H), 0.89 (t,
J = 6.4 Hz, 3H); 13C-NMR (75 MHz, CDCl3) δ 150.8, 149.5, 143.1, 137.7, 132.4, 128.9, 128.5, 127.8, 123.7
(2C), 119.0, 116.8, 59.5, 56.9, 55.1, 44.8, 34.9, 34.7, 31.7, 29.8, 28.7, 25.8 (2C), 24.3, 24.2, 22.6, 14.1; IR
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(neat) 2926, 2853, 1666, 1540, 1449, 1346, 1173, 744, 698 νmax/cm−1; MS (ESI) m/z Calcd for C29H39N4+:
443.3170; found: 443.3170 [M + H]+.
(E)-methyl2-((3-hexyl-2-phenethyl-2,3-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-4(1H)-ylidene)
amino)acetate (67). The crude material was purified by column chromatography Pet/EtOAc 95:5 and
Pet/EtOAc 90:10) to give the product as yellow oil (145 mg, yield 65%). 1H-NMR (300 MHz, CDCl3) δ
8.53–8.50 (m, 1H), 7.70–7.67 (m, 1H), 7.34–7.15 (m, 7H), 4.38 (d, J = 18.3 Hz, AB system, 1H), 4.33 (br
d, 1H), 4.15 (d, J = 18.0 Hz, AB system, 1H), 3.90–3.77 (m, 5H), 2.93–2.78 (m, 4H), 1.84–1.51 (m, 3H),
1.37–1.23 (m, 7H), 0.91–0.87 (m, 3H); 13C-NMR (75 MHz, CDCl3) δ 170.5, 156.7, 149.3, 142.9, 139.6,
132.2, 128.9, 128.6, 126.5, 124.5, 124.3, 119.1, 116.9, 57.5, 57.1, 52.4, 50.8, 44.6, 35.2, 31.8, 29.4, 29.0, 26.2,
22.7, 14.1; IR (neat) 2928, 2885, 1746, 1670, 1451, 1375, 1200, 1174, 746, 699 νmax/cm−1; MS (ESI) m/z
Calcd for C27H35N4O2+: 447.2755; found: 447.2757 [M + H]+.
(E)-N-(7-hexyl-6-(4-methoxyphenyl)-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)-2-
methylpropan-2-amine (68). The crude material was purified by column chromatography
(n-hexane/ EtOAc 97:3) to give the product as brownish solid (162 mg, 85% yield). 1H-NMR (400 MHz,
CDCl3) δ 8.34 (s, 1H), 7.08 (d, J = 8.4 Hz, 2H), 6.77 (d, J = 8.4 Hz, 2H), 6.65 (s, 1H), 5.03 (s, 1H), 3.71 (s,
3H), 3.52 (dd, Jab = 16.4 Hz, 2H), 2.62–2.48 (m, 2H), 1.56–1.49 (m, 2H), 1.35–1.26 (m, 6H), 1.20 (s, 9H),
0.86–0.83 (m, 3H); 13C-NMR (100 MHz, CDCl3) δ 159.2, 144.2, 132.9, 129.7, 127.5, 125.8, 124.5, 113.8,
62.7, 55.1, 54.5, 53.6, 40.5, 31.6, 31.3, 28.1, 26.8, 22.5, 14.0. IR (neat) 2965, 2929, 2861, 2833, 1668, 1511,
1460, 1338, 1246, 1037, 819 νmax/cm−1; Mp 78–79 ◦C; MS (ESI) m/z Calcd for C23H35N4O+: 383.2806;
found: fragment ion (loss of 2-methyl-N-methylenepropan-2-amine moiety): 300.2072 [M + H]+.
(E)-4-(5-(tert-butylimino)-7-hexyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazin-6-yl)-N,N-dimethylaniline
(69). The crude material was purified by column chromatography (n-hexane/ EtOAc 85:15) to give the
product as yellowish solid (49 mg, 25% yield). 1H-NMR (400 MHz, CDCl3) δ 8.36 (s, 1H), 7.01 (d,
J = 8.0 Hz, 2H), 6.68 (s, 1H), 6.60 (d, J = 8.0 Hz, 2H), 5.03 (s, 1H), 3.57 (dd, Jab = 15.2 Hz, 2H), 2.91 (s,
6H), 2.62–2.49 (m, 2H), 1.58–1.52 (m, 2H), 1.39–1.30 (m, 6H), 1.24 (s, 9H), 0.90–0.87 (m, 3H); 13C-NMR
(100 MHz, CDCl3) δ 150.0, 144.7, 132.9, 129.4, 126.1, 124.4, 122.5, 112.0, 62.8, 54.4, 53.6, 40.7, 40.3, 31.7,
31.3, 29.7, 28.2, 26.8, 22.6, 14.0. IR (neat) 3115, 2952, 2926, 2857, 1669, 1529, 1466, 1349, 1206, 1192, 811
νmax/cm−1; Mp 104–105 ◦C; MS (ESI) m/z Calcd for C24H38N5+: 396.3122; found: fragment ion (loss of
2-methyl-N-methylenepropan-2-amine moiety): 313.2388 [M + H]+.
(E)-N-(7-hexyl-6-(naphthalen-2-yl)-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)-2-
methylpropan-2-amine (70). The crude material was purified by column chromatography
(n-hexane/ EtOAc 90:10) to give the product as yellowish solid (32 mg, 16% yield). 1H-NMR (400
MHz, CDCl3) δ 8.48 (s, 1H), 7.83–7.72 (m, 3H), 7.54 (s, 1H), 7.50–7.44 (m, 3H), 6.70 (s, 1H), 5.27 (s,
1H), 3.58 (dd, Jab = 16.4 Hz, 2H), 2.72–2.61 (m, 2H), 1.66–1.59 (m, 2H), 1.42–1.29 (m, 6H), 1.26 (s, 9H),
0.93–0.90 (m, 3H); 13C-NMR (100 MHz, CDCl3) δ 143.9, 140.4, 133.6, 133.0, 132.9, 128.5, 128.1, 127.5,
127.2, 126.5, 126.4, 126.3, 125.7, 124.7, 63.5, 54.7, 53.9, 40.8, 31.7, 31.3, 28.3, 26.8, 22.6, 14.1. IR (neat) 3120,
3055, 2964, 2930, 2857, 1669, 1464, 1347, 1362, 1203, 795 νmax/cm−1; Mp 108–109 ◦C; MS (ESI) m/z Calcd
for C26H35N4+: 403.2857; found: fragment ion (loss of 2-methyl-N-methylenepropan-2-amine moiety):
320.2123 [M + H]+.
(E)-N-(6-(4-chlorophenyl)-7-hexyl-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)-4-
methoxyaniline (71). The crude material was purified by column chromatography (n-hexane/ EtOAc
85:15) to give the product as colorless to yellowish oil (72 mg, 33% yield). 1H-NMR (400 MHz, CDCl3)
δ 8.49 (s, 1H), 7.30 (d, J = 8.4 Hz, 2H), 7.13 (d, J = 8.4 Hz, 2H), 6.82 (s, 1H), 6.77–6.74 (m, 2H), 6.60–6.58
(m, 2H), 4.77 (s, 1H), 3.76 (s, 3H), 3.66 (dd, Jab = 16.8 Hz, 2H), 2.62–2.42 (m, 2H), 1.46–1.39 (m, 2H),
1.32–1.21 (m, 6H), 0.88–0.85 (m, 3H); 13C-NMR (100 MHz, CDCl3) δ 156.7, 148.6, 139.1, 134.3, 134.0,
133.1, 129.6, 129.0, 125.6, 125.4, 121.1, 114.3, 60.7, 55.4, 53.7, 41.2, 31.6, 27.7, 26.6, 22.5, 14.0. IR (neat)
2927, 2855, 1666, 1505, 1462, 1395, 1351, 1242, 1210, 1090, 833 νmax/cm−1; MS (ESI) m/z Calcd for
C25H30ClN4O+: 437.2103; found: 437.2107 [M + H]+.
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(E)-N-(7-(4-methoxybenzyl)-6-(4-methoxyphenyl)-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)
cyclohexanamine (72). The crude material was purified by column chromatography (n-hexane/ EtOAc
70:30) to give the product as yellowish oil (202 mg, 91% yield). 1H-NMR (400 MHz, CDCl3) δ 8.46 (s,
1H), 7.29 (d, J = 8.4 Hz, 2H), 7.15 (d, J = 8.4 Hz, 2H), 6.89 (d, J = 8.4 Hz, 2H), 6.84 (d, J = 8.4 Hz, 2H),
6.74 (s, 1H), 4.95 (s, 1H), 3.82 (s, 3H), 3.79 (s, 3H), 3.77–3.73 (m, 1H), 3.65–3.57 (m, 3H), 3.13–3.07 (m,
1H), 1.74–1.01 (m, 10H); 13C-NMR (100 MHz, CDCl3) δ 159.5, 159.1, 145.8, 132.8, 130.0, 129.6, 129.3,
126.8, 125.4, 124.8, 114.0, 113.9, 58.7, 57.4, 56.7, 55.2 (2C), 40.8, 34.1, 33.4, 25.4, 24.1, 24.0. IR (neat) 2928,
1676, 1598, 1509, 1459, 1345, 1249, 1201, 1033, 732, 698 νmax/cm−1; MS (ESI) m/z Calcd for C27H33N4O2+:
445.2599; found: 445.2600 [M + H]+.
(E)-N-(7-(4-methoxybenzyl)-6-phenethyl-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)
cyclohexanamine (73). The crude material was purified by column chromatography (n-hexane/ EtOAc
70:30) to give the product as off-white solid (216 mg, 98% yield). 1H-NMR (400 MHz, CDCl3) δ 8.31 (s,
1H), 7.27–7.10 (m, 7H), 6.84 (d, J = 8.4 Hz, 2H), 6.76 (s, 1H), 4.14–4.10 (m, 1H), 3.80 (s, 3H), 3.81–3.72 (m,
2H), 3.59–3.43 (m, 2H), 2.95–2.70 (m, 3H), 2.17–2.13 (m, 1H), 1.73–1.00 (m, 11H); 13C-NMR (100 MHz,
CDCl3) δ 159.2, 147.8, 140.9, 130.2, 129.8, 128.5 (4C), 126.2, 125.0, 124.4, 113.8, 58.2, 56.3, 55.3, 54.3, 39.7,
34.3, 34.0, 31.6, 31.4, 25.4, 24.2. IR (neat) 3022, 2933, 2858, 1661, 1513, 1467, 1349, 1252, 1220, 1037, 815
νmax/cm−1; Mp 119–120 ◦C; MS (ESI) m/z Calcd for C28H35N4O+: 443.2806; found: 443.2805 [M + H]+.
(E)-N-(7-(4-methoxybenzyl)-6-phenyl-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)-2,4,4-
trimethylpentan-2-amine (74). The crude material was purified by column chromatography
(n-hexane/ EtOAc 80:20) to give the product as colorless to yellowish oil (206 mg, 93% yield). 1H-NMR
(400 MHz, CDCl3) δ 8.43 (s, 1H), 7.33–7.19 (m, 7H), 6.90 (d, J = 8.0 Hz, 2H), 6.73 (s, 1H), 5.14 (s, 1H),
3.82 (s, 3H), 3.73 (s, 2H), 3.57 (dd, Jab = 16.4 Hz, 2H), 1.53 (dd, Jab = 14.4 Hz, 2H), 1.17 (s, 3H), 1.03 (s,
3H), 0.95 (s, 9H); 13C-NMR (100 MHz, CDCl3) δ 159.1, 142.0, 135.6, 129.8, 129.7, 128.7, 128.6, 128.2,
125.7, 124.7, 113.9, 62.3, 58.7, 58.4, 57.5, 55.3, 40.7, 31.9, 31.8, 30.7. IR (neat) 2953, 1674, 1511, 1459, 1338,
1246, 1207, 1191, 699, 654 νmax/cm−1; MS (ESI) m/z Calcd for C28H37N4O+: 445.2962; found: fragment
ion (loss of 2,4,4-trimethyl-N-methylenepentan-2-amine moiety): 306.1602 [M + H]+.
(E)-N-(7-(4-methoxybenzyl)-6-phenethyl-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)
naphthalen-1-amine (75). The crude material was purified by column chromatography (n-hexane/
EtOAc 70:30) to give the product as yellowish solid (182 mg, 75% yield). 1H-NMR (400 MHz, CDCl3) δ
8.47 (s, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.60 (d, J = 7.6 Hz, 1H), 7.48–7.42 (m,
2H), 7.26 (s, 1H), 7.14 (d, J = 8.0 Hz, 2H), 6.96–6.59 (m, 9H), 3.99 (dd, Jab = 16.8 Hz, 2H), 3.81 (s, 3H),
3.76–3.72 (m, 1H), 3.61 (dd, Jab = 13.2 Hz, 2H), 2.68–2.48 (m, 2H), 2.11–2.04 (m, 1H), 1.85–1.76 (m, 1H);
13C-NMR (100 MHz, CDCl3) δ 159.1, 151.9, 144.1, 139.8, 134.0, 133.4, 130.7, 129.9, 129.3 (2C), 128.0,
127.9, 127.7, 127.3, 126.4, 125.9, 125.7, 124.9, 124.8, 120.6, 115.6, 113.9, 58.1, 55.3, 55.0, 39.7, 31.1, 29.8. IR
(neat) 3052, 2954, 2937, 2846, 1667, 1510, 1356, 1246, 1208, 1031, 862 νmax/cm−1; Mp 136–137 ◦C; MS
(ESI) m/z Calcd for C32H31N4O+: 487.2493; found: 487.2498 [M + H]+.
(E)-2-methyl-N-(6-phenethyl-7-phenyl-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)propan-2-
amine (76). The crude material was purified by column chromatography (n-hexane/ EtOAc 70:30) to
give the product as colorless to brownish oil (173 mg, 93% yield). 1H-NMR (400 MHz, CDCl3) δ 8.18 (s,
1H), 7.31–7.15 (m, 7H), 6.93–6.87 (m, 4H), 4.72–4.69 (m, 1H), 4.58 (s, 2H), 2.97–2.70 (m, 2H), 2.31–1.97
(m, 2H), 1.15 (s, 9H); 13C-NMR (100 MHz, CDCl3) δ 150.2, 144.8, 140.2, 129.4, 128.7, 128.5, 126.4, 125.2,
123.9, 121.6, 118.9, 58.2, 54.4, 38.9, 32.1, 31.4, 31.3. IR (neat) 2967, 2924, 1678, 1598, 1494, 1458, 1344,
1201, 924, 754, 697 νmax/cm−1; MS (ESI) m/z Calcd for C24H29N4+: 373.2387; found: fragment ion (loss
of 2-methyl-N-methylenepropan-2-amine): 290.1654 [M + H]+.
2-methyl-N-(6-pentyl-7-phenyl-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)propan-2-amine
(77). The crude material was purified by column chromatography (n-hexane/ EtOAc 90:10) to give the
product as yellowish oil (160.5 mg, 95% yield). 1H-NMR (400 MHz, CDCl3) main isomer δ 8.16 (s, 1H),
7.23–7.19 (m, 2H), 6.91–6.86 (m, 4H), 4.84–4.80 (m, 1H), 4.48 (dd, Jab = 16.8 Hz, 2H), 1.96–1.87 (m, 1H),
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1.65–1.52 (m, 3H), 1.37–1.17 (m, 4H), 1.27 (s, 9H), 0.86–0.83 (m, 3H); 13C-NMR (100 MHz, CDCl3) main
isomer δ 156.4, 145.4, 140.6, 129.4, 127.1, 123.6, 121.3, 118.5, 59.1, 55.6, 38.7, 31.4, 31.3, 28.6, 25.9, 22.5,
13.9. IR (neat) 2959, 2930, 2870, 1672, 1493, 1456, 1361, 1201, 1103, 750, 695νmax/cm−1; MS (ESI) m/z
Calcd for C21H31N4+: 339.2544; found: fragment ion (loss of 2-methyl-N-methylenepropan-2-amine):
256.1810 [M + H]+.
N-(6-isobutyl-7-phenyl-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)cyclohexanamine (78).
The crude material was purified by column chromatography (n-hexane/ EtOAc 90:10) to give the
product as yellowish oil (157.5 mg, 90% yield). 1H-NMR (400 MHz, CDCl3) main isomer δ 8.22 (s, 1H),
7.22–7.18 (m, 2H), 6.89–6.84 (m, 4H), 4.91–4.87 (m, 1H), 4.51 (dd, JAB = 16.8 Hz, 2H), 3.47–3.42 (m, 1H),
1.97–1.11 (m, 13H), 0.98–0.96 (m, 6H); 13C-NMR (100 MHz, CDCl3) main isomer δ 174.4, 149.9, 133.0,
129.4, 124.9, 123.9, 121.1, 117.7, 70.07, 53.6, 43.7, 39.3, 34.1, 33.1, 25.5, 24.5, 24.4, 23.6. IR (neat) 2928,
2855, 1671, 1598, 1497, 1463, 1354, 1216, 924, 754, 693 νmax/cm−1; MS (ESI) m/z Calcd for C22H31N4+:
351.2544; found: 351.2543 [M + H]+.
(E)-N-(6-(4-chlorophenyl)-7-hexyl-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)-2-methylpropan-
2-amine (79). The crude material was purified by column chromatography (n-hexane/ EtOAc 97:3)
to give the product as an off-white solid (137 mg, 71% yield). 1H-NMR (400 MHz, CDCl3) δ 8.35 (s,
1H), 7.24 (d, J = 8.4 Hz, 2H), 7.15 (d, J = 8.4 Hz, 2H), 6.67 (s, 1H), 5.05 (s, 1H), 3.53 (dd, Jab = 16.8 Hz,
2H), 2.64–2.51 (m, 2H), 1.57–1.50 (m, 2H), 1.34–1.24 (m, 6H), 1.21 (s, 9H), 0.88–0.85 (m, 3H); 13C
NMR (100 MHz, CDCl3) δ 143.4, 134.5, 134.0, 133.0, 129.9, 128.7, 125.4, 124.8, 62.7, 54.6, 53.8, 40.5,
31.6, 31.3, 28.1, 26.7, 22.6, 14.0. IR (neat) 2949, 2933, 2865, 2815, 1665, 1489, 1458, 1340, 1202, 1088,
1013 νmax/cm−1; Mp 108–109 ◦C; MS (ESI) m/z Calcd for C22H32ClN4+: 387.2310; found: fragment ion
(loss of 2-methyl-N-methylenepropan-2-amine): 304.1577 [M + H]+.
(E)-N-(6-(4-chlorophenyl)-7-(4-methoxybenzyl)-7,8-dihydroimidazo[1,5-a]pyrazin-5(6H)-ylidene)
cyclohexanamine (80). The crude material was purified by column chromatography (n-hexane/EtOAc
70:30) to give the product as amorphous solid (205 mg, 91.5% yield). 1H-NMR (400 MHz, CDCl3) δ
8.46 (s, 1H), 7.31–7.18 (m, 6H), 6.89 (dd, J = 8.4 Hz, 2H), 6.75 (s, 1H), 4.93 (s, 1H), 3.82 (s, 3H), 3.77–3.59
(m, 4H), 3.08–3.02 (m, 1H), 1.75–1.01 (m, 10H); 13C NMR (100 MHz, CDCl3) δ 159.2, 144.9, 134.2, 133.7,
130.0, 129.5, 129.3, 128.9, 125.1, 125.0 (2C), 114.0, 58.4, 57.6, 56.8, 55.3, 40.9 (2C), 34.1, 33.4, 25.4, 24.1,
24.0. IR (neat) 2929, 2854, 1669, 1511, 1463, 1348, 1247, 1190, 1090, 815, 731 νmax/cm−1; MS (ESI) m/z
Calcd for C26H30ClN4O+: 449.2103; found: 449.2106 [M + H]+.
4. Conclusions
In conclusion, in this manuscript we reported the one-pot multicomponent synthesis of substituted
imidazopyrazines, starting from simple and easily available building blocks. Three covalent bonds and
one six-membered ring were formed with this transformation under very mild reaction conditions and
without the need of metal catalysts or protecting groups. Furthermore, the good to excellent yields, the
ease of performance, and the possibility to use two different regioisomeric imidazolemethanamines and
a benzimidazolic congener, make this novel transformation a very powerful tool to simply generate
complexity and diversity.
This work demonstrated how, with the judicious choice of components, it is still possible to discover
new productive interrupted Ugi reactions, after fifty years from the first report [39]. Furthermore,
the drug-like nature of these compounds, along with their novelty, and therefore lack of intellectual
properties, makes them interesting probes for medicinal chemistry applications. Studies on this topic
are in progress and will be reported in due course.
Supplementary Materials: The following are available online: copies of 1H and 13C spectra; X-ray data for 79
(CIF file, CCDC number 1884698).
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